

Supplemental Table S1. Risk of Repeat Revascularization According to Patients' Prescribed Glucose Lowering Agents among New Users

	No.	Repeat PCI	Duration	IR, /1,000 PY	HR (95% CI)				
					Model 1	Model 2	Model 3	Model 4	Model 5
Insulin									
No	4,743	462	21,258.20	21.73	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	1,159	108	5,101.00	21.17	0.97 (0.79–1.20)	0.98 (0.79–1.21)	0.98 (0.78–1.22)	0.97 (0.78–1.20)	0.96 (0.77–1.19)
Sulfonylurea									
No	4,693	449	20,744.33	21.64	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	1,209	121	5,614.87	21.55	1.03 (0.84–1.26)	1.02 (0.83–1.25)	1.03 (0.78–1.36)	1.07 (0.81–1.41)	1.07 (0.811–1.42)
Metformin									
No	3,033	292	13,503.34	21.62	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	2,869	278	12,855.86	21.62	1.01 (0.85–1.19)	0.99 (0.84–1.17)	0.97 (0.72–1.29)	0.91 (0.68–1.22)	0.91 (0.68–1.23)
Meglitinides									
No	5,823	558	26,017.69	21.45	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	79	12	341.52	35.14	1.65 (0.93–2.92)	1.68 (0.95–2.97)	1.72 (0.96–3.10)	1.73 (0.96–3.12)	1.76 (0.97–3.16)
TZD									
No	5,841	568	26,105.51	21.76	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	61	2	253.69	7.88	0.35 (0.09–1.40)	0.362 (0.09–1.45)	0.35 (0.09–1.43)	0.35 (0.09–1.43)	0.36 (0.09–1.44)
DPP4i									
No	4,929	478	22,151.90	21.58	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	973	92	4,207.30	21.87	1.00 (0.80–1.25)	0.98 (0.79–1.23)	0.96 (0.72–1.29)	0.98 (0.73–1.32)	0.98 (0.73–1.32)
AGI									
No	5,736	552	25,519.39	21.63	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Yes	166	18	839.81	21.43	1.07 (0.67–1.72)	1.06 (0.66–1.69)	1.06 (0.65–1.73)	1.05 (0.64–1.71)	1.02 (0.62–1.67)

The incidence rate is presented per 1,000 person-years (PY).

Model 1: Adjusted for age and sex; Model 2: Adjusted model 1+adjusted for household income, hypertension, dyslipidemia, current smoking, alcohol, regular exercise, and body mass index; Model 3: Adjusted model 2+adjusted for use of insulin, number of oral antidiabetic drugs; Model 4: Adjusted model 3+adjusted for fasting blood glucose; Model 5: Adjusted model 4+adjusted for duration of diabetes.

PCI, percutaneous coronary intervention; IR, incidence rate; HR, hazard ratio; CI, confidence interval; TZD, thiazolidinedione; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, alpha glucosidase inhibitor.